ARCT-810 generally safe and well tolerated, demonstrating encouraging activity across key urea cycle biomarkers in ongoing Phase 2 study

LUNAR 2.0™ produces greater than 30-fold higher protein expression in multiple NHP studies – unlocks new therapeutic opportunities

ARCT-2601, an OTC deficiency therapeutic candidate utilizing LUNAR 2.0™, to be integrated by YE 2026 into ongoing Phase 2 study as advised by the FDA

Arcturus to acquire myNEO, an AI discovery company, to improve mRNA design quality, accelerate innovation, and enhance target identification capability

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.